lung adenocarcinoma
Conditions
Interventions
Lobectomy group:Lobotomy and systematic lymph node dissection were performed, including at least 3 stations of N1 and 3 stations of N2. Tumor dissection was performed on the left mediastinum 4L, at le
Pulmonary segmental resection group:Segmentation pulmonary resection and systematic lymph node dissection were performed, including at least 3 stations of N1 and 3 stations of N2 lymph nodes. Tumor di
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. Aged 20 to 79 years, gender is not limited; 2. Preoperative CT indicated that the diameter of the tumor was less than 2 cm, and the anatomical location of the tumor could be treated with either standard segmental resection or lobectomy; 3. Imaging findings were peripheral single nodules or accompanying lesions with microinfiltration and below; 4. Good lung function (FEV1 > 1.5 L or FEV1% >= 60%), able to tolerate both segmental and lobectomy; 5. Standard anatomic lobectomy or resection of lung segments (including single and combined lung segments) was performed during the operation; 6. Intraoperative freezing indicated a negative incisional margin, and systemic lymph node dissection was performed; 7. The intraoperative pathological diagnosis was invasive lung adenocarcinoma with micropapillae and solid subtypes accounting for > 5%; 8. Physical condition score ECOG 0 ~ 2; 9. Voluntarily participate in and sign informed consent, and be able to comply with the study visit plan and other program requirements.
Exclusion criteria
Exclusion criteria: 1. Preoperative imaging examination or mediastinal lymph node puncture indicated positive preoperative lymph nodes; 2. Patients with distant metastasis or chest or ascites found in preoperative examination; 3. Prior to tumor resection, anti-tumor therapy in any form, including interventional chemoembolization, ablation, radiotherapy, chemotherapy and molecular targeted therapy, etc.; 4. Patients with other malignant tumors or blood diseases; 5. The investigator assessed patients unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival rate;Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Perioperative mortality;Incidence of operative complications;Postoperative hospital stay;Drainage tube extubation time; | — |
Countries
China
Contacts
Public ContactZhao Deping
Outcome results
None listed